Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
- Astellas, Shared Lab Operators Link Up on Life Science Ecosystem
October 12, 2023
- Donanemab’s Limited Duration of Dosing Benefits Patients on Safety Front: Lilly CSO
October 11, 2023
- Japan Ethical Drug Sales Surge 8.1% in August: Crecon
October 10, 2023
- Kyowa Kirin to Acquire Orchard to Forge Ahead in Gene Therapy
October 6, 2023
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
- Opdivo Snatches Back Top Spot in Japan Sales Ranking in September: Encise
October 6, 2023
- Sawai Bags CML Nod for Sprycel Generic
October 5, 2023
- JCR to Explore Best Opportunities for Overseas Alliance on JR-171: Exec
October 5, 2023
- Manlio Florenzano Takes Helm of Sandoz Japan as Spin-Off Completes
October 5, 2023
- Nippon Kayaku Buys Stake in Adlai to Drive Cancer Drug Collab
October 5, 2023
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
- Takeda to Pull Lung Cancer Med Exkivity in US after Trial Miss
October 4, 2023
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
- Tarlige Tops July Rep Promotion Ranking, Takes Back Crown from Mounjaro for GPs: Intage
October 3, 2023
- Kyorin to Cut Non-Sales Jobs through Voluntary Buyout
October 3, 2023
- FDA Gives Thumbs-Down for MEDRx/DWTI’s Lidocaine Patch
October 3, 2023
- Nihon Servier Launches Blood Cancer Med Oncaspar in Japan
October 3, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…